REsearch Report Life

ResearchMoz presents professional and in-depth study of "Global Respiratory Drugs Market 2016-2020". Asthma, COPD, allergic rhinitis, pulmonary hypertension, cystic fibrosis, and IPF are some of the major respiratory diseases. Among these, asthma and COPD are the most prevalent worldwide. Environmental pollution, changing lifestyles, and hereditary factors are some of the common causes of respiratory diseases. Intranasal corticosteroids, antihistamines, immunosuppressants, bronchodilators, and leukotriene antagonists are the respiratory medicines that are commonly used for the treatment of mild-to-moderate respiratory diseases. However, the choice of drug depends on the type and severity of the disease. Technavios analysts forecast the global respiratory drugs market to grow at a CAGR of 6.48% during the period 2016-2020. Covered in this report The report covers the present scenario and the growth prospects of the global respiratory drugs market for 2016-2020. To calculate ...

ResearchMoz presents this most up-to-date research on Global Respiratory Drugs Market to 2022 - Pipeline and Market Characterized by Growing Prominence of Targeted Therapies, with Asthma and Cystic Fibrosis Leading the Way. The respiratory therapy area consists of indications that affect the respiratory system in different ways, such as the scarring of lung tissue, and excessive production of mucus in the airways, thereby decreasing lung function. Some of the key indications in this therapy area include asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF) and idiopathic pulmonary fibrosis (IPF). The causes of respiratory disorders vary significantly across each indication, and include factors such as environment, occupation, genetic predisposition and aging. The treatment landscape for respiratory disorders has traditionally been dominated by small molecule therapies that aim to treat the disease symptoms, rather than the cause. This means that treatment options...